Ratios
10-year key figure history for Lipum turnover, profit, dividend, equity, PE and PB.
Stockprice
Price movement for Lipum with index and moving average MA50 and MA200.
Description
Lipum has developed a biological drug candidate, SOL-116, for the treatment of autoimmune and autoinflammatory diseases. The drug candidate has applied for a patent with the possibility of market exclusivity until the year 2040. SOL-116 is in a late preclinical phase after extensive tests with promising data from models for the rheumatic diseases Juvenile Idiopathic Arthritis (JIA) and Rheumatoid Arthritis (RA). Furthermore, completed preclinical studies support that the candidate in the long run should also be able to be used in a number of different types of chronic inflammatory diseases with great medical needs.